Long Covid and Digital Health in Switzerland: Potentials and Limitations.

Publication date: May 21, 2026

Post-COVID-19 (or Long Covid) presents a complex and persistent health challenge affecting a growing number of individuals worldwide. Digital health interventions (DHIs) offer potential support for symptom monitoring, self-management, and information access. However, their availability, quality, and sustainability remain uncertain, particularly in smaller healthcare markets such as Switzerland. This study provides a descriptive assessment of ten representative DHIs for Long Covid available from Switzerland. Each tool was evaluated using a 19-item framework derived from validated instruments. Three independent reviewers tested all interventions on iOS and Android devices, with consensus ratings across five quality categories. Results showed strong usability (average 6. 3/8) and practical usefulness (5/8), but consistent weaknesses in accessibility (3. 7/8) and data protection (4. 6/8). Total scores ranged from 14. 7 to 26. 3 out of 38. Several Swiss-based apps were discontinued during the study period, highlighting market fragility. Findings underscore the need for inclusive design, transparent data practices, and institutional support if DHIs are to complement Long Covid care sustainably.

Open Access PDF

Concepts Keywords
Android Accessibility
Covid App evaluation
Discontinued COVID-19
Healthcare Digital Health
Swiss Digital health intervention
Humans
Long Covid
Mobile Applications
SARS-CoV-2
Switzerland
Telemedicine
Usability

Semantics

Type Source Name
disease MESH Long Covid
disease MESH COVID-19
drug DRUGBANK Pentaerythritol tetranitrate
drug DRUGBANK Methyltestosterone

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *